Novo Holdings, a Danish investment firm, has recently announced its plans to acquire Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. The deal, valued at $11.5 billion, is part of Novo Holdings' strategy to expand production capacity for its obesity drug, Wegovy.
Wegovy, also known as semaglutide, is an injectable medication used for chronic weight management. It has gained significant attention and popularity due to its effectiveness in aiding weight loss. Novo Nordisk, a pharmaceutical company owned by Novo Holdings, developed this breakthrough treatment. With the growing demand for Wegovy, Novo Holdings aims to secure its supply by acquiring Catalent, which currently manufactures the drug.
